Paul Wenz
Illumina
3 Papers
Paul Wenz is an academic researcher from Illumina. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Diana M. Merino,Lisa M. McShane,David Fabrizio,Vincent Funari,Shu-Jen Chen,James R. White,Paul Wenz,Jonathan F. Baden,J. Carl Barrett,Ruchi Chaudhary,Li Chen,Wangjuh (Sting) Chen,Jen-Hao Cheng,Dinesh Cyanam,Jennifer S Dickey,Vikas Gupta,Matthew D. Hellmann,Elena Helman,Yali Li,Joerg Maas,Arnaud Papin,Rajesh Patidar,Katie Quinn,Naiyer A. Rizvi,Hongseok Tae,Christine K. Ward,Mingchao Xie,Ahmet Zehir,Chen Zhao,Manfred Dietel,Albrecht Stenzinger,Mark Stewart,Jeff Allen +32 more
TL;DR: Encouraging uptake of TMB as a predictive biomarker in the clinic creates an urgent need to bring stakeholders together to agree on the harmonization of key aspects of panel-based TMB estimation, such as the standardization of T MB reporting, standardized of analytical validation studies and the alignment ofPanel TMB values with a reference standard.
452
925P Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples
Li Liu,Karl Roessler,Sven Bilke,Yi Ding,D. Erlandson,Y. Fu,Bharath Hariharan,Sigrid Katz,J. Lee,C. A. Schulman,Fan Song,Raakhee Vijayaraghavan,Paul Wenz,E. Xia,H. Yan,Y. B. Zhu,C Zhao,Janel Dockter,Traci Pawlowski,Justin Christopher Day +19 more
TL;DR: The TruSight Oncology 500 (TSO 500 HRD) as mentioned in this paper was developed by adding an HRD probe pool targeting genome-wide single nucleotide polymorphisms (SNPs) to the TSO 500 to enable Genomic Instability Score (GIS) assessment.
2
Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administration–Approved Next-Generation Sequencing–Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples
Nitin Udar,Anita Iyer,Margaret Porter,Robert Haigis,Shannon E. Smith,Shivani Dhillon,Kristen Meier,Diane Ward,Jing Lu,Paul Wenz,Leonard Buchner,Tamsen Dunn,Aaron Wise,Amy Mueller,Karen Gutekunst +14 more
TL;DR: This assay can clearly distinguish single-stranded artifacts from low frequency mutations, is accurate, precise, and reproducible, can achieve consistent detection of a mutation at 5% mutation frequency, exhibits minimal impact from tested interfering substances, and can simultaneously detect 56 mutations in a single run.